Nuvation Bio Inc. Cash Flow Statement
NUVB / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Nuvation Bio Inc. used $173M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$204.6M | -$567.9M | -$75.8M | -$104.2M | -$86.8M | -$41.7M |
| Depreciation & Amortization | $1.7M | $683.0K | $222.0K | $199.0K | $184.0K | $103.0K |
| Operating Cash Flow | -$173.4M | -$130.4M | -$68.0M | -$96.1M | -$68.2M | -$36.5M |